Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - COLLEGIUM PHARMACEUTICAL, INC | a16-6452_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 15, 2016
COLLEGIUM PHARMACEUTICAL, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Virginia |
|
001-37372 |
|
03-0416362 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
780 Dedham Street
Suite 800
Canton, MA 02021
(781) 713-3699
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 |
Results of Operations and Financial Condition. |
On March 15, 2016, Collegium Pharmaceutical, Inc. issued a press release announcing its financial results for the annual period ended December 31, 2015. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under Item 2.02 of this Current Report on Form 8-K.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits:
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press Release dated March 15, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: March 16, 2016 |
Collegium Pharmaceutical, Inc. | |
|
|
| |
|
|
By: |
/s/ Paul Brannelly |
|
|
|
Name: Paul Brannelly |
|
|
|
Title: Executive Vice President and Chief Financial Officer |